Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Completed

Conditions: Venous Thromboembolism

Treatments: Biological: Extra Blood Draw

Study type: Interventional

Funder types: Other

Identifiers

NCT02904967

2012-30

2012-A01139-34 (Other Identifier)

Details and patient eligibility

About

Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years.

Reduce the risk of recurrence is a serious public health issue. For this it is necessary to identify patients at high risk of recurrence. However, until now, only 50% of recurrences are in the presence of known risk factors, suggesting that there are still yet unidentified risk factors.

The assumption behind this project is that there are specifically associated genetic polymorphisms to the risk of VTE recurrence.

The aim of our project is to identify these polymorphisms from genome-wide data MARTHA cohort. This cohort is composed of 1542 subjects from the Marseille region with at least one episode of VTE documented. Patients in the cohort MARTHA have all been genotyped for approximately 500,000 polymorphisms.

The investigators want to achieve a case-control study nested in the cohort MARTHA. Subjects with recurrent VTE (the case) will be compared to subjects with only one episode of VTE (the controls). The allelic frequencies of polymorphisms previously genotyped 500,000 will be compared between cases and controls. The identification of these new genetic variants associated with VTE recurrence should allow us to improve the pathophysiological knowledge of the disease, reduce the frequency of episodes and focus research on new therapeutic approaches.

Enrollment: 221 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Caucasian topic
• Personal history of VTE confirmed by the reference diagnostic tests

Exclusion criteria

• Pregnant or breastfeeding women

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

221 participants in 2 patient groups

patients with recurrent VTE

Experimental group

Treatment:

Biological: Extra Blood Draw

patients with only one episode of VTE

Active Comparator group

Treatment:

Biological: Extra Blood Draw